2025-03-31 18:37:00
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Bliss GVS Pharma Q3FY22 consolidated loss at Rs. 50.11 crore
Posted On : 2022-01-29 22:41:51( TIMEZONE : IST )
Bliss GVS Pharma Limited has reported Consolidated financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 222.2942 crores during the period ended December 31, 2021 as compared to Rs. 201.4374 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. -50.1122 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 21.2662 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. -4.74 for the period ended December 31, 2021 as compared to Rs. 2.01 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹ 222.2942 crs | ₹201.4374 crs |  10.35% |
| Net Profit | ₹-50.1122 crs | ₹21.2662 crs |  -335.64% |
| EPS | ₹-4.74 | ₹2.01 | -335.82% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 222.2942 crores during the period ended December 31, 2021 as compared to Rs.168.1766 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.-50.1122 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.25.5506 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.-4.74 for the period ended December 31, 2021 as compared to Rs.2.43 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹ 222.2942 crs | ₹168.1766 crs | 32.18% |
| Net Profit | ₹-50.1122 crs | ₹25.5506 crs | -296.13% |
| EPS | ₹-4.74 | ₹2.43 | -295.06% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.599.6942 crores during the 9 Months period ended December 31, 2021 as compared to Rs.459.0497 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.-4.5918 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.62.2488 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.-0.43 for the 9 Months period ended December 31, 2021 as compared to Rs.5.91 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹599.6942 crs | ₹459.0497 crs | 30.64% |
| Net Profit | ₹-4.5918 crs | ₹62.2488 crs | -107.38% |
| EPS | ₹-0.43 | ₹5.91 | -107.28% |
Shares of Bliss GVS Pharma Limited was last trading in BSE at Rs. 97.25 as compared to the previous close of Rs. 96.50. The total number of shares traded during the day was 16344 in over 440 trades.
The stock hit an intraday high of Rs. 98.80 and intraday low of 96.90. The net turnover during the day was Rs. 1598535.00.
